Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding the Status of Share Repurchases
Position and Policy Regarding Reduction of the Investment Unit
Notice Regarding the Difference of Nonconsolidated Financial Results as Compared to Actual Results for the Previous Year
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [IFRS]
Notice Regarding Share Repurchase and Cancellation of Treasury Stock
Otsuka, 27% Decrease in Net Income for The Current Fiscal Year
Otsuka Holdings Corporate Governance Report
Otuaka Holdings Corporate Governance Report
Otsuka Receives FDA Accelerated Approval for VOYXACT(sibeprenlimab-szsi)
Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025
Consolidated Financial Results for the Nine-Month Period Ended September 30, 2025 [IFRS]
Otsuka, Jan-Sep (Cumulative 3Q) Net Income Increases by 55%, Jul-Sep Net Income Increases by 48%
Integrated Report 2025
(Progress of Disclosure)Notice of Completion of Share Transfer of Equity-Method Affiliate
Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI
Notice Regarding Partial Amendment to “Notification of Change of Equity Method Affiliate (Transfer of Shares)”
Notice of Payment of Interim Dividend and Revision of Annual Dividend Forecast
Otsuka, Net Income Forecast for the Fiscal Year Revised Upward by 20%, Dividend Revised Upward by 20 Yen
Consolidated Financial Results for the Six-Month Period Ended June 30, 2025 [IFRS]
Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2025